Septerna (NASDAQ:SEPN) SVP Sells $126,087.39 in Stock

Key Points

• Septerna SVP Daniel Long sold 3,333 shares at an average price of $37.83, generating $126,087.39 and reducing his direct holdings by 3.34% to 96,412 shares.
• Septerna shares fell 1.9% to $36.80, while the clinical-stage biotech reported better-than-expected quarterly results, including an adjusted loss of $0.29 per share versus the $0.43 consensus estimate and revenue of $26.75 million.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $52.44; several firms recently raised their targets to between $48 and $51.

Septerna, Inc. (NASDAQ:SEPN - Get Free Report) SVP Daniel Long sold 3,333 shares of Septerna stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $37.83, for a total transaction of $126,087.39. Following the completion of the sale, the senior vice president directly owned 96,412 shares of the company's stock, valued at approximately $3,647,265.96. This trade represents a 3.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Septerna Stock Down 1.9%

SEPN traded down $0.70 during trading on Thursday, hitting $36.80. The company's stock had a trading volume of 241,541 shares, compared to its average volume of 459,468. The firm has a market cap of $1.72 billion, a PE ratio of -68.15 and a beta of 2.30. The business's 50 day simple moving average is $37.46 and its 200-day simple moving average is $31.15. Septerna, Inc. has a one year low of $13.67 and a one year high of $51.10.

Septerna (NASDAQ:SEPN - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.14. The firm had revenue of $26.75 million for the quarter, compared to the consensus estimate of $19.22 million. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. Equities research analysts expect that Septerna, Inc. will post -1.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Septerna

Institutional investors and hedge funds have recently modified their holdings of the stock. TRV GP V LLC bought a new stake in Septerna in the second quarter worth $208,160,143. TRV GP VI LLC purchased a new position in shares of Septerna during the 2nd quarter worth about $141,048,460. BlackRock Inc. bought a new position in Septerna during the 2nd quarter valued at about $64,706,000. Jupiter Topco LLC bought a new stake in Septerna in the second quarter worth about $43,723,000. Finally, Goldman Sachs Group Inc. lifted its stake in Septerna by 86.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company's stock worth $75,698,000 after purchasing an additional 1,260,409 shares during the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on SEPN shares. Wells Fargo & Company increased their price target on Septerna from $48.00 to $50.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 12th. Raymond James Financial reaffirmed a "strong-buy" rating and set a $49.00 price objective on shares of Septerna in a report on Tuesday, August 11th. Guggenheim boosted their target price on shares of Septerna from $45.00 to $51.00 and gave the stock a "buy" rating in a report on Tuesday, August 11th. Stifel Nicolaus set a $49.00 target price on shares of Septerna in a research report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. raised their target price on shares of Septerna from $38.00 to $48.00 and gave the company an "overweight" rating in a research note on Wednesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Septerna presently has a consensus rating of "Moderate Buy" and an average target price of $52.44.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source